All In Biotech

Drug Trial Radar · NCT05324631

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Non-Radiographic Axial Spondyloarthritis Subjects

Last checked: Nov 19, 2026Latest source record: Sep 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 16, 2022

Primary completion

Aug 30, 2024

Study completion Dec 11, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of SHR0302 in subjects with active non-radiographic axial spondyloarthritis.

Conditions

  • Non-radiographic Axial Spondyloarthritis

Interventions

  • SHR0302Drug

    SHR0302, oral, once daily

  • SHR0302 placeboDrug

    SHR0302 placebo, oral, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) 40 Response at week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.